USA flag logo/image

An Official Website of the United States Government

DRUG CHALLENGE ASSAY FOR USE IN THROMBOLYTIC THERAPY

Award Information

Agency:
Department of Health and Human Services
Branch:
N/A
Award ID:
16730
Program Year/Program:
1993 / SBIR
Agency Tracking Number:
16730
Solicitation Year:
N/A
Solicitation Topic Code:
N/A
Solicitation Number:
N/A
Small Business Information
Biotherm, Inc.
5301 Departure Drive Raleigh, NC 27604
View profile »
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
 
Phase 2
Fiscal Year: 1993
Title: DRUG CHALLENGE ASSAY FOR USE IN THROMBOLYTIC THERAPY
Agency: HHS
Contract: N/A
Award Amount: $500,000.00
 

Abstract:

A TEST SYSTEM FOR RAPID SCREENING OF PATIENTS PRIOR TO INITIATION OF THROMBOLYTIC THERAPY WILL BE DEVELOPED. THIS SYSTEM WILL BE BASED ON A NOVEL DRY REAGENT ASSAY TECHNOLOGY WHICH RECENTLY HAS BEEN APPLIED SUCCESSFULLY TO PT AND ACTIVATED PTT TESTS. INTRODUCTION OF A RAPID CONVENIENT TEST OF PATIENT (OR CLOT) LYTIC POTENTIAL FOR USE ON A DECENTRALIZED BASIS COULD PROVIDE EARLY INDICATION OF LIKELIHOOD OF SUCCESS WITH STREPTOKINASE SOONER THAN EXISTING LABORATORY METHODS AND COULD SERVE AS AN IMPORTANT DIAGNOSTIC GUIDE IN THROMBOLYTIC THERAPY. WE WILL DEVELOP THIS TEST SYSTEM AND TO ASSESS ITS POTENTIAL USING A COMBINATION OF LABORATORY STUDIES AND CLINICAL SAMPLE STUDIES. APPLICATION TO EARLY DETERMINATION OF CLOT LYSIS RESPONSE IN PATIENTS PRIOR TO THROMBOLYTIC THERAPY WILL BE EXPLORED. THIS WORK WILL BE PERFORMED IN CONJUNCTION WITH INVESTIGATORS AT UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL. PHASE I SUPPORT WOULD FUND ASSAY OPTIMIZATION ACTIVITIES AND CLINICAL SAMPLE FEASIBILITY STUDIES.

Principal Investigator:

Oberhardt, Bruce J
Principal Investigator
9195442952

Business Contact:

1 r43 hl47223-01
Small Business Information at Submission:

Biotherm, Inc.
P O Box 13417 Res Triangle Park, NC 27709

EIN/Tax ID: 562098302
DUNS: N/A
Number of Employees: N/A
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No